Synergistic effects of calcium-channel and angiotensin-receptor blockers on endothelial function and inflammatory responses in a porcine drug-eluting stent model

Circulation Journal

Volumn 74, Issue 8, 2010, Pages 1704-1710

  Kubota, Naozumi ^a   Miyauchi, Katsumi ^a   Kasai, Takatoshi ^a   Iesaki, Takafumi ^a   Kajimoto, Kan ^a   Sumiyoshi, Katsuhiko ^a   Dohi, Tomotaka ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Endothelial function; Infammation; Sirolimus eluting stent; Vasodilation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; AZELNIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CELL ADHESION MOLECULE; CLOPIDOGREL; OLMESARTAN; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; FEMALE; INFLAMMATORY DISEASE; MONOTHERAPY; NONHUMAN; PROTEIN EXPRESSION; RANDOMIZATION; SWINE; VASODILATATION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; CALCIUM CHANNEL BLOCKERS; DRUG SYNERGISM; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; INFLAMMATION; SWINE; VASODILATION;

EID: 77955075770     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0743     Document Type: Article

References (31)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. Randomized study with the sirolimus-coated bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions: A randomized comparison of a siro-limus-eluting stent with a standard stent for coronary revasculariza-tion. N Engl J Med 2002; 346: 1773-1780.
3. Rodriguez AE, Mieres J, Fernandez-Pereira C, Vigo CF, Rodriguez-Alemparte M, Berrocal D, et al. Coronary stent thrombosis in the current drug-eluting stent era: Insights from the ERACI III trial. J Am Coll Cardiol 2006; 47: 205-207.
4. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-eluting stent and coronary thrombosis: Biological mechanisms and clinical implications. Circulation 2007; 115: 1051-1508.
5. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441.
6. Lim SY, Jeong MH, Hong SJ, Lim do S, Moon JY, Kim JH, et al. Infammation and delayed endothelialization with overlapping drug-eluting stents in a porcine model of in-stent restenosis. Circ J 2008; 72: 463-468.
7. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, et al. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004; 43: 263-269.
8. Ohtani K, Egashira K, Ihara Y, Nakano K, Funakoshi K, Zhao G, et al. Angiotensin II type 1 receptor blockade attenuates in-stent restenosis by inhibiting infammation and progenitor cells. Hypertension 2006; 48: 664-670.
9. Kobayashi N, Ohno T, Yoshida K, Fukushima H, Mamada Y, Nomura M, et al. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in Dahl salt-sensitive hypertensive rats. Am J Hypertens 2008; 21: 576-581.
10. Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S, et al. Olmesartan, but not amlodipine, improves endothelium-depen-dent coronary dilation in hypertensive patients. J Am Coll Cardiol 2007; 50: 1144-1149.
11. Kimura Y, Hirooka Y, Sagara Y, Sunagawa K. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide syn-thase in the brain and inhibits sympathetic nerve activity. Clin Exp Hypertens 2007; 29: 13-21.
12. Dens J, Desmet W, Piessens J. An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty. Am Heart J 2003; 145: 404-408.
13. Hosoya M, Ohashi J, Sawada A, Takaki A, Shimokawa H. Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-defcient mice. Circ J 2010; 74: 798-806.
14. Li J, Jabara R, Pendyala L, Otsuka Y, Shinke T, Hou D, et al. Abnormal vasomotor function of porcine coronary arteries distal to sirolimus-eluting stents. JACC Cardiovasc Interv 2008; 1: 279-285.
15. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, et al. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992; 19: 267-274.
16. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 1997; 29: 808-816.
17. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits: Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 1996; 16: 1312-1318.
18. Yokoyama T, Miyauchi K, Kurata T, Satoh H, Daida H. Inhibitory effcacy of pitavastatin on the early infammatory response and neointimal thickening in a porcine coronary after stenting. Atherosclerosis 2004; 174: 253-259.
19. Ross R, Faggiotto A, Bowen-Pope D, Raines E. The role of endo-thelial injury and platelet and macrophage interactions in atherosclerosis. Circulation 1984; 70: III-77-III-82.
20. Bechara C, Wang X, Chai H, Lin P, Yao Q, Chen C. Growth-related oncogene-α induces endothelial dysfunction through oxidative stress and downregulation of eNOS in porcine coronary arteries. Am J Physiol Heart Circ Physiol 2007; 293: 3088-3095.
21. Ohtani K, Egashira K, Ihara Y, Nakano K, Funakoshi K, Zhao G, et al. Angiotensin II type 1 receptor blockade attenuates in-stent restenosis by inhibiting infammation and progenitor cells. Hypertension 2006; 48: 664-670.
22. Otsuka A, Azuma K, Iesaki T, Sato F, Hirose T, Shimizu T, et al. Temporary hyperglycaemia provokes monocyte adhesion to endo-thelial cells in rat thoracic aorta. Diabetologia 2005; 48: 2667-2674.
23. Iesaki T, Gupte SA, Kaminski PM, Wolin MS. Inhibition of gua-nylate cyclase stimulation by NO and bovine arterial relaxation to peroxynitrite and H2O2. Am J Physiol 1999; 277: 978-985.
24. Kasai T, Miyauchi K, Yokoyama T, Kajimoto K, Sumiyochi K, Kubota N, et al. Pioglitazone attenuates neointimal thickening via suppression of the early infammatory response in a porcine coronary after stenting. Atherosclerosis 2008; 197: 612-619.
25. Miyauchi K, Kasai T, Yokayama T, Aihara K, Kurata T, Kajimoto K, et al. Effectiveness of statin-eluting stent on early infammatory response and neointimal thickness in a porcine coronary model. Circ J 2008; 72: 832-838.
26. Hadjadj S, Cloutier I, Geoffroy P, Tanguay J. Stent implantation in coronary porcine arteries is associated with early activation of TNFα and TNFα receptor II expression. Atherosclerosis 2007; 192: 25-32.
27. Zhou Z, Lauer MA, Wang K, Forudi F, Zhou X, Song X, et al. Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. Atherosclerosis 2002; 161: 153-159.
28. Fliser D, Buchholz K, Haller H; European Trial on Olmesartan and Pravastatin in Infammation and Atherosclerosis (EUTOPIA) Investigators. Antiinfammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinfammation. Circulation 2004; 110: 1103-1107.
29. Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M, et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterol-emic rabbits. J Am Coll Cardiol 2007; 49: 1482-1489.
30. Ma J, Kishida S, Wang GQ, Meguro K, Imuta H, Oonuma H, et al. Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells. J Cardiovasc Pharmacol 2006; 47: 314-321.
31. Nakano K, Egashira K, Tada H, Kohjimoto Y, Hirouchi Y, Kitajima S, et al. A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates. J Hypertens 2006; 24: 1881-1889.